Get the Daily Brief
Latest Biotech News
Danaher to buy Masimo for $9.9B to bulk up diagnostics
Danaher Corp. agreed to acquire Masimo for $9.9 billion in cash—about a 38.3% premium—purchasing all outstanding shares at $180 each to strengthen its diagnostics portfolio. The deal folds...
Korsana raises $175M to chase Alzheimer’s antibody slot
Korsana Biosciences launched with $175 million in financing to develop an anti‑amyloid antibody, KRSA‑028, targeting delivery across the blood‑brain barrier. The company plans a 2027 clinical...
Axpaxli meets superiority endpoint vs Eylea in Phase 3 — market reaction mixed
Ocular Therapeutix reported that Axpaxli (OTX‑TKI), a bioresorbable intravitreal hydrogel incorporating axitinib, met its primary superiority endpoint against a low‑dose Eylea comparator in the...
UCLA lipid nanoparticles insert full‑length CFTR gene in airway cells
Researchers at UCLA demonstrated a lipid nanoparticle‑based gene‑editing platform capable of precisely inserting a full‑length healthy CFTR gene into human airway cells, a step toward a universal...
Sensei rescues Faeth: reverse merger supplies new lead cancer asset and $200M
Sensei Biotherapeutics acquired Faeth Therapeutics in an all‑stock deal that effectively functions as a reverse merger and generated a $200 million private placement as part of the transaction....
FDA reverses course: will review Moderna’s flu vaccine
The U.S. Food and Drug Administration accepted Moderna’s amended application for its mRNA influenza vaccine after initially refusing to review the submission. Moderna and the agency agreed an...
Psilocybin scores again: Compass nears NDA after second Phase III win
Compass Pathways reported a second positive Phase III trial for its synthetic psilocybin candidate COMP360, achieving the primary endpoint in treatment‑resistant depression and prompting the...
Korsana launches with $175M to test anti‑amyloid Alzheimer's antibody
Korsana Biosciences announced a $175 million Series A to advance KRSA‑028, an anti‑amyloid antibody aimed at Alzheimer’s disease, and launched out of Paragon Therapeutics with plans for clinical...
Ocular’s Axpaxli tops low‑dose Eylea in Phase III – market reaction mixed
Ocular Therapeutix reported that its Axpaxli therapy met the superiority primary endpoint versus a low‑dose Eylea control in the Sol‑1 Phase III trial for wet age‑related macular degeneration,...
FDA rejects Disc’s bitopertin: CRL raises questions about surrogate endpoint use
The FDA issued a complete response letter for Disc Medicine’s bitopertin in erythropoietic protoporphyria (EPP), concluding the surrogate biomarker reductions (PPIX) did not reliably predict...
Nektar resurfaces: rezpeg maintenance data fuels stock surge and $460M offering
Nektar Therapeutics announced positive Phase IIb maintenance data for rezpegaldesleukin (rezpeg) in atopic dermatitis showing high EASI‑75 and EASI‑90 response rates in maintenance dosing cohorts,...
Nanoparticle gene editing inserts full gene into airway cells – CF therapy advance
UCLA researchers unveiled a lipid nanoparticle gene‑editing platform capable of inserting a full‑length healthy gene into human airway cells, addressing a key delivery and payload size limitation...
Boehringer halts inhaled CF gene program after Phase I/II readout
Boehringer Ingelheim discontinued development of its inhaled lentiviral gene therapy BI‑3720931 for cystic fibrosis following Phase I/II data that failed to show efficacy. The company reported the...
FDA moves to curb compounded GLP‑1 weight‑loss drugs – Hims & Hers flagged
The FDA announced plans to crack down on active pharmaceutical ingredients used by compounding pharmacies to produce off‑label GLP‑1 weight‑loss formulations, explicitly calling out major...
Danaher to buy Masimo for $9.9B – diagnostics push accelerates
Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion in cash at $180 per share, representing a roughly 38% premium, to expand Danaher’s diagnostics and monitoring capabilities. The...
Compass psilocybin nears NDA – second Phase III hit
Compass Pathways reported a second positive Phase III trial for its synthetic psilocybin candidate COMP360, and is preparing to push a rolling NDA toward U.S. regulators. The company disclosed two...
Ocular’s Axpaxli beats Eylea in Phase III – superiority met
Ocular Therapeutix said its intravitreal Axpaxli (OTX‑TKI) met the superiority primary endpoint versus a low-dose aflibercept (Eylea) comparator in the Sol‑1 Phase III trial for wet age-related...
Danaher to buy Masimo: $9.9 billion diagnostics push
Danaher agreed to acquire Masimo for $9.9 billion cash, offering $180 per share in a transaction that values Masimo at a roughly 38% premium to its prior close. Danaher said the deal will bolster...
Nektar rezpeg maintenance data fuels comeback — Phase IIb success
Nektar Therapeutics reported positive blinded maintenance data from its 52‑week Phase IIb REZOLVE‑AD trial of rezpegaldesleukin (rezpeg) in moderate‑to‑severe atopic dermatitis, driving a sharp...
FDA rejects Disc’s bitopertin — voucher program’s first negative outcome
The FDA issued a Complete Response Letter (CRL rejecting Disc Medicine’s bitopertin for erythropoietic protoporphyria (EPP), marking a notable negative outcome for a drug chosen for an accelerated...